Dienogest
Abstract
The progestogen dienogest exhibits highly selective binding to the progesterone receptor. It has high progestational and significant antiandrogenic activity, but only moderate antigonadotrophic activity. Dienogest inhibits ovulation, produces secretory transformation of the endometrium and has antiproliferative effects. Oral dienogest 2 mg/day plus ethinylestradiol 30 micrograms/day provides effective contraception (Pearl Index approximately 0.2). Cycle stability is good during long term use of this combination; irregular vaginal bleeding was evident in 6% of women after 12 months' use. Androgenic symptoms (including hirsutism, seborrhoea, alopecia, acne vulgaris and hair and skin greasiness) improved in women treated with dienogest plus ethinylestradiol. The adverse events associated with dienogest are typical of those expected of a progestogen. The drug does not produce androgenic adverse effects and has little clinically significant effect on metabolic, lipid and haemostatic parameters.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
DNG exerts strong antiandrogenic properties and has no glucocorticoid or mineralocorticoid effects.
“Moreover, DNG exerts strong antiandrogenic properties, whereas it has no glucocorticoid nor mineral corticoid effects [22,23].”
From Oral and depot progestin therapy for endometriosis: towards a personalized medicine (2017) · cites this paper as [23]
The citation lists haven’t been fetched yet
References 38 · Cited by 87
- Authors
- Foster, R. H., & Wilde, M. I.
- Corresponding author
- Foster, Rachel H.
- ORCID
- Foster, Rachel H.
- Venue
- Drugs
- Published
- 1998
- Volume
- 56
- Issue
- 5
- Pages
- 825-833
- ISSN
- 0012-6667 (ISSN-L)
- OpenAlex
- W3190789610
- Cited by
- 87
- References
- 38
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 5 · 2023: 18 · 2022: 2 · 2021: 4 · 2020: 3 · 2019: 1 · 2018: 2 · 2017: 6 · 2016: 2 · 2015: 2 · 2014: 3 · 2013: 5
- FWCI
- 0.43
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Drugs (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Reproductive Health and Contraception
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Estrogen and related hormone effects
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- dienogest, progestogens, progesterone receptor, antiandrogenic activity, ovulation inhibition, antiproliferative activity, oral contraceptives, ethinyl estradiol, Pearl index, irregular vaginal bleeding, hirsutism, lipid profile, hemostatic parameters
- MeSH terms
- Androgen Antagonists, Animals, Clinical Trials as Topic, Contraceptives, Oral, Ethinyl Estradiol, Female, Humans, Nandrolone, Progestins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
